Table 2. The association between HAART use and incidence of Kaposi's sarcoma of the MACS HIV-infected men in current study, stratified by current smoking status and HAART use.

	KS incidence cases	Follow-up (person-years)b	Unadjusted model			Adjusted modela
			HR	95% CI	P-value	HR	95% CI	P-value
Current Smoking: no	336	15 609
HAART ever use
No			Ref.			Ref.
Yes			0.08	0.06–0.12	<0.0001*	0.28	0.16–0.49	<0.0001*
Current Smoking: yes	192	10 949
HAART ever use
No			Ref.
Yes			0.13	0.08–0.20	<0.0001*	0.60	0.28–1.12	0.10
HAART use: no	55	13 094
Current smoking
No			Ref.			Ref.
Yes			0.78	0.64–0.94	0.01*	0.57	0.35–0.92	0.02*
HAART use: yes	473	13 164
Current smoking
No			Ref.			Ref.
Yes			1.20	0.71–2.05	0.50	1.09	0.52–2.92	0.82

Abbreviations: CI: confidence interval; HR=hazard ratio; Ref.=Reference category.

^aThe model was adjusted for age, race/ethnicity, employment status, education, individual gross income, enrolment, and CD4 cell count.

^bThe follow-up time was for both KS and non-KS incidence cases.

*: P-value<0.05.